Stay updated with breaking news from Sera Prognostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sera Prognostics, Inc. (NASDAQ:SERA – Get Free Report) CEO Zhenya Lindgardt sold 26,867 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $8.11, for a total value of $217,891.37. Following the completion of the transaction, the chief executive officer now owns 869,245 shares […]
SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® , focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
Marquette Asset Management LLC reduced its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA – Free Report) by 9.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 32,139 shares of the company’s stock after selling 3,548 shares during the period. Marquette Asset Management LLC’s holdings in Sera Prognostics were worth $192,000 at […]
Acuitas Investments LLC lowered its stake in shares of Sera Prognostics, Inc. (NASDAQ:SERA – Free Report) by 30.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 121,258 shares of the company’s stock after selling 51,937 shares during the period. Acuitas […]
CARLSBAD, Calif., April 01, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a